Sri Lanka

Population 2018: 21 million

### Tuberculosis profile

#### Estimates of TB burden, 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>14 (10–18)</td>
<td>64 (47–83)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.056 (0.034–0.084)</td>
<td>0.27 (0.16–0.4)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.026 (&lt;0.01–0.079)</td>
<td>0.12 (0.01–0.37)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.81 (0.66–0.98)</td>
<td>3.8 (3.1–4.6)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.018 (0.011–0.028)</td>
<td>0.09 (0.05–0.13)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

- **New cases**: 0.1% (0–0.5)
- **Previously treated cases**: 3.3% (1.8–5.5)

#### TB case notifications, 2018

- **Total new and relapse**: 8 620
  - % tested with rapid diagnostics at time of diagnosis: 2%
  - % with known HIV status: 92%
  - % pulmonary: 71%
  - % bacteriologically confirmed: 73%
  - % children aged 0–14 years: 3%
  - % women: 34%
  - % men: 63%
- **Total cases notified**: 8 856

#### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2018**: 64% (49–86)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 6% (4–9)
- **TB/HIV care in new and relapse TB patients, 2018**: Number (%)
  - Patients with known HIV status who are HIV-positive: 34 <1%
  - on antiretroviral therapy: 34 100%

#### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance:
  - New cases: 30%
  - Previously treated cases: 91%

#### Laboratory-confirmed cases*

- MDR/RR-TB: 32, XDR-TB: 1

#### Patients started on treatment**

- MDR/RR-TB: 13, XDR-TB: 1

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 32%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 48% (44–52)

### TB financing, 2019

- National TB budget (US$ millions): 5.1
- Funding source: 70% domestic, 30% international, 0% unfunded

---

*Ranges represent uncertainty intervals

MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*Calculated for pulmonary cases only

*Includes cases with unknown previous TB treatment history

**Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2019-10-18 Data: www.who.int/tb/data